scholarly journals BADARASHMA PISHTI - AN OVERVIEW

2020 ◽  
pp. 175-176
Author(s):  
Ravindra. G. Varma ◽  
S. K. Bannigol
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Urine Volume ◽  
Bladder Capacity ◽  
Urethral Pressure ◽  
Urinary Flow ◽  
Urinary Disorders ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

Badarashma resembles like a fruit of Badara. Pishti is also known as Sange Yahood Pishti, Ber Pathar Pishti, lime Silicate. It is a fossilized stone primarily containing silicate of lime. Aging increases the risk of urinary disorders, especially after 5th decade. Lower urinary tract symptoms are more prevalent among the elderly and various clinical studies have also demonstrated advancing age to be associated with a reduced bladder capacity, increase in prostate size which ultimately leads to increase in uninhibited contractions, decreased urinary flow rate, diminished urethral pressure, increased post voidal residual urine volume and many a times lower urinary tract symptoms also. There are so many Ayurvedic drugs which have proven to be the best. Badarashma Pisthi is a comprehensive natural remedy for any kind of urinary obstruction or any other urinary disorders. The main health and therapeutic properties of Badarashma Pisthi is diuretic, lithotriptic and analgesic.

Possibilities of phytotherapy in patients with lower urinary tract symptoms due to benign prostate enlargement

2020 ◽  
Vol 10 (4) ◽  
pp. 317-323
Author(s):  
Adel S. Al-Shukri ◽  
Stanislav V. Kostyukov
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Prostate Gland ◽  
Urine Volume ◽  
Good Tolerability ◽  
Clinical Indicators ◽  
Urinary Tract Symptoms ◽  
Main Component ◽  
Lower Urinary

The results of the use of the phytopreparation Tadimax in the treatment of 60 men with mild and moderate lower urinary tract symptoms (LUTS) developed as a result of benign enlargement of the prostate gland are presented. The average age of the patients was 66.5 3.8 years. Tadimax was prescribed 2 tablets 3 times a day, in courses of 7 days with 7 day breaks for 3 months (a total of 6 courses). The data obtained indicate high efficacy and good tolerability of treatment. A decrease in the severity of LUTS was noted in 59 (96.6%) patients, which was accompanied by significant changes in objective clinical indicators: a decrease in residual urine volume and an increase in urine flow rate. Tadimax is a combined preparation, which includes extracts of several medicinal plants, and the main component is Crinum latifolium. The therapeutic effect of Tadimax is based on anti-inflammatory, antiproliferative and immunotropic action.

scholarly journals The reliability and reproducibility of ultrasonography for measuring the residual urine volume in men with lower urinary tract symptoms

2014 ◽  
Vol 12 (4) ◽  
pp. 285-289 ◽  
Author(s):  
Hassan A. Abdelwahab ◽  
Housseini M. Abdalla ◽  
Mahmoud H. Sherief ◽  
Mohamed B. Ibrahim ◽  
Mostafa A. Shamaa
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Urine Volume ◽  
Residual Urine Volume ◽  
Residual Urine ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

scholarly journals Prospective randomized controlled study directly comparing tadalafil and tamsulosin for male patients with lower urinary tract symptoms

2018 ◽  
Author(s):  
Takumi Takeuchi ◽  
Satoshi Toyokawa ◽  
Yumiko Okuno ◽  
Noriko Ishida ◽  
Masanari Yamagoe ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Urine Volume ◽  
Maximum Flow ◽  
Controlled Study ◽  
Night Time ◽  
Once Daily ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

AbstractLower urinary tract symptoms are widespread in elderly men and often suggestive of benign prostatic hyperplasia (LUTS/BPH). A randomized, prospective, and open-labeled trial directly comparing the effects of tadalafil (a phosphodiesterase 5 inhibitor) 5 mg once daily and tamsulosin (an α1-blocker) 0.2 mg once daily for 12 weeks in LUTS/BPH patients was conducted. Data were recorded before randomization as well as at 4, 8, and 12 weeks after medication. Fifteen patients allocated tadalafil and 20 allocated tamsulosin completed 12 weeks of medication. Total IPSS, IPSS voiding, and IPSS-QOL scores declined with medication, but there was no difference between drugs. IPSS storage scores reduced more in the tamsulosin group than tadalafil group. OABSS did not decline significantly with medication. IIEF5 was maintained in the tadalafil group, but declined in the tamsulosin group. The maximum flow rate and post-void residual urine volume did not significantly change with medication. Daytime, night-time, and 24-hour urinary frequencies as well as the mean and largest daytime, night-time, and 24-hour voiding volumes per void did not significantly change with medication. In conclusion, tamsulosin was more effective to reduce storage symptoms than tadalafil. Tadalafil had the advantage of maintaining the erectile function.

scholarly journals The Add-On Effect of Solifenacin for Patients with Remaining Overactive Bladder after Treatment with Tamsulosin for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction

2010 ◽  
Vol 2010 ◽  
pp. 1-5 ◽  
Author(s):  
Naoya Masumori ◽  
Taiji Tsukamoto ◽  
Masahiro Yanase ◽  
Hiroki Horita ◽  
Masaharu Aoki
Keyword(s):  
Urinary Tract ◽  
Overactive Bladder ◽  
Symptom Score ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Urine Volume ◽  
Real Life ◽  
Benign Prostatic Obstruction ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

Objectives. To investigate the add-on effect of solifenacin for Japanese men with remaining overactive bladder (OAB) symptoms after tamsulosin monotherapy for lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO) in real-life clinical practice.Methods. Patients aged ≥ 50 having remaining OAB symptoms (≥ 3 of OAB symptom score (OABSS) with ≥2 of urgency score) after at least 4 weeks treatment by 0.2 mg of tamsulosin for BPO/LUTS received 2.5 or 5.0 mg of solifenacin for 12 weeks. The International Prostate Symptom Score (IPSS), QOL index and OABSS, maximum flow rate (Qmax) and postvoid residual urine volume (PVR) were determined.Results. A total of 48 patients (mean age 72.5 years) completed the study. There were significant improvement in IPSS (15.1 to 11.2) and QOL index (4.2 to 3.0) by add-on of solifenacin. Although the IPSS storage symptom score was significantly improved, there were no changes observed in the IPSS voiding symptom score. The OABSS showed significant improvement (8.0 to 4.8). No changes were observed in Qmax and PVR.Conclusions. Under the supervision of an experienced urologist, the additional administration of solifenacin to patients with BPO/LUTS treated with tamsulosin, is effective in controlling remaining OAB symptoms.

scholarly journals Clinical and Urodynamic Predictors of the Q-Tip Test in Women With Lower Urinary Tract Symptoms

2020 ◽  
Vol 24 (1) ◽  
pp. 52-58
Author(s):  
Chin-Jui Wu ◽  
Wan-Hua Ting ◽  
Ho-Hsiung Lin ◽  
Sheng-Mou Hsiao
Keyword(s):  
Urinary Tract ◽  
Lower Urinary Tract Symptoms ◽  
Stress Incontinence ◽  
Lower Urinary Tract ◽  
Regression Coefficient ◽  
Urodynamic Stress Incontinence ◽  
Urethral Pressure ◽  
Urinary Tract Symptoms ◽  
Tip Test ◽  
Lower Urinary

Purpose: The Q-tip test is used to measure urethral hypermobility and can predict surgical outcomes. However, certain factors may affect the reliability of this test. Our aim was to identify independent clinical and urodynamic predictors of the results of the Q-tip test.Methods: Between January 2014 and June 2019, 176 consecutive women with lower urinary tract symptoms who underwent the Q-tip test and urodynamic studies were included in this retrospective study.Results: Multivariable regression analysis revealed that age (regression coefficient, -0.55), point Ba (regression coefficient, 4.1), urodynamic stress incontinence (regression coefficient, 9.9), maximum flow rate (Qmax) (regression coefficient, 0.13), pressure transmission ratio (PTR) at maximum urethral pressure (MUP) (regression coefficient, -0.14), and the score on the fifth question of the Incontinence Impact Questionnaire (IIQQ5; “Has urine leakage affected your participation in social activities outside your home?”; regression coefficient, -4.1) were independent predictors of the Q-tip angle, with a constant of 87.0. The following Spearman rank correlation coefficients were found between the Q-tip angle and the following variables: age, -0.38; point Ba, 0.34; urodynamic stress incontinence, 0.32; Qmax, 0.28; PTR at MUP, -0.28; and IIQQ5, -0.23. A receiver operating characteristic curve (ROC) analysis for the prediction of urodynamic stress incontinence found that the optimum cutoff for PTR at MUP was <81%, with an area under the ROC curve of 0.70.Conclusions: Age, point Ba, urodynamic stress incontinence, Qmax, PTR at MUP, and IIQQ5 were independent predictors of the Q-tip angle. However, none of these could be used as effective surrogates for the Q-tip test due to their lack of a sufficient correlation.

scholarly journals Tadalafil 5 mg Alone or in Combination with Tamsulosin 0.4 mg for the Management of Men with Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Prospective Observational Trial

2019 ◽  
Vol 8 (8) ◽  
pp. 1126 ◽  
Author(s):  
Arcangelo Sebastianelli ◽  
Pietro Spatafora ◽  
Jacopo Frizzi ◽  
Omar Saleh ◽  
Maurizio Sessa ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Urinary Tract ◽  
Combination Therapy ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Urinary Flow ◽  
Observational Trial ◽  
Paired Samples ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

Tadalafil 5 mg represents the standard for men with Erectile dysfunction (ED) and lower urinary tract symptoms (LUTS)/benign prostatic enlargement (BPE). We carried out an observational trial aiming to assess the efficacy and safety of Tadalafil compared with Tadalafil plus Tamsulosin. Seventy-five patients complaining of ED and LUTS were treated for 12-weeks with Tadalafil plus placebo (TAD+PLA-group) or with combination therapy tadalafil plus tamsulosin (TAD+TAM-group). Efficacy variables were: International Index of Erectile Function (IIEF), International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax) and safety assessments. Data were evaluated using paired samples T-test (baseline vs. 12-weeks) and analysis of variance (Δgroup-TAD+PLA vs. Δgroup-TAD+TAM). At baseline, both groups presented similar characteristics and symptoms scores (all: p > 0.05). From baseline to 12-weeks, all the subjects showed a significant improvement of IIEF, total-IPSS, storage-IPSS, Qmax (all: p < 0.001). Conversely, a significant improvement of voiding-IPSS was observed in TAD+TAM-group (−3.5 points, p < 0.001). Indeed, TAD+PLA-group showed a not significant improvement of voiding-IPSS (−2.0 points, p = 0.074). When we compared between-groups differences at 12-weeks, IIEF (p = 0.255), total-IPSS (p = 0.084) and storage-IPSS (p = 0.08) did not show any statistically significant differences, whereas, voiding-IPSS and Qmax were significantly better in TAD+TAM-group (p = 0.006 and p = 0.027, respectively). No severe treatment adverse events (TAEs) were reported in both groups. Tadalafil achieved the same improvements of IIEF, total-IPSS, storage-IPSS when compared to combination therapy. Instead, Qmax and voiding-IPSS were better managed with combination therapy, without change of TAEs.

Sign in / Sign up

Export Citation Format

Share Document